Table 3. Odds ratios of RAL+DRV/r vs TDF/FTC+DRV/r for proportion with a ‘very satisfied’ response on the HIVTSQ at W96 and impact of adjusting for potential confounders by logistic regression.
| Treatment satisfaction Question at W96 (% very satisfied (5 or 6)) |
RAL+DRV/r | TDF/FTC + DRV/r | Unadjusted OR (95% CI) for RAL vs TDF/FTC | Adjusted OR* | Other significant factors in model (OR (95%CI)) |
|---|---|---|---|---|---|
| Satisfied with current treatment | 238/268 (89%) | 269/288 (93%) | 1.78 (0.98, 3.25); p=0.06 | 1.55 (0.75, 3.19); p=0.24 | Age (1.03 (95%CI 1.0-1.08)) |
| Satisfaction with how well HIV was controlled | 250/268 (93%) | 277/287 (97%) | 1.99 (0.90, 4.40); p=0.09 | 1.99 (0.77, 5.18); p=0.16 | HIV symptom score change from baseline (0.92 (95% CI 0.89-0.96)), and EQ5D VAS change from baseline (1.03 (95%CI 1.00-1.06)), |
| Satisfied with extent of unwanted side effects | 234/267 (88%) | 250/287 (87%) | 0.95 (0.58, 1.57); p=0.85 | 0.88 (0.48, 1.60); p=0.67 | HIV symptom score change from baseline (0.96 (95%CI 0.94-0.99)) |
| Satisfaction with how demanding treatment is | 180/267 (67%) | 220/286 (77%) | 1.61 (1.11, 2.34); p=0.01 | 1.43 (0.91, 2.24); p=0.12 | HIV symptom score change from baseline (0.98 (95%CI 0.95-1.00)), age (1.03 (95%CI 1.00-1.05)) and gender (2.72 (95%CI 1.03-7.18)) |
| Convenience | 209/268 (78%) | 249/287 (87%) | 1.84 (1.18, 2.89); p=0.007 | 1.86 (0.08, 3.23); p=0.03 | HIV symptom score change from baseline (0.96 (95%CI 0.94-0.99) |
| Flexibility of treatment | 176/271 (65%) | 217/285 (76%) | 1.72 (1.19, 2.49); p=0.004 | 1.54 (0.99, 2.38); p=0.06 | CES-d score change from baseline (0.96 (95%CI 0.93-0.98)), age (1.02 (95%CI 1.00-1.05)), gender (3.44 (95%CI 1.30-9.10)) |
| Satisfaction with understanding of HIV | 232/266 (87%) | 252/287 (88%) | 1.05 (0.64, 1.74); p=0.84 | 1.08 (0.60, 1.94); p=0.78 | |
| Extent with which treatment fits into lifestyle | 203/264 (77%) | 250/287 (87%) | 2.03 (1.29, 3.17); p=0.002 | 2.12 (1.22, 3.66); p=0.007 | |
| Recommendation to a friend | 230/266 (86%) | 267/288 (93%) | 1.99 (1.13, 3.51); p=0.02 | 2.21 (1.09, 4.51); p=0.03 | |
| Continuation of treatment | 230/266 (86%) | 252/286 (88%) | 1.16 (0.70, 1.92); p=0.56 | 1.43 (0.77, 2.63); p=0.26 | EQ5D VAS score change from baseline (0.97 (95%CI 0.95-0.99)), CES-d score change from baseline (0.95 (95%CI 0.91-0.99)). |
*
adjusted for change from baseline in CES-d, Symptom scale and EQ5D VAS and baseline factors: age (years), and gender (transgender male to female = female, odds ratios estimated for female vs male).